Unregulated Peptides Gain Popularity Amid Safety Concerns in Gray Market

Unapproved synthetic peptides have surged in popularity as users seek benefits in physical performance and health optimization. These short chains of amino acids function as signaling molecules but are marketed without regulatory oversight. An industry for their production and distribution operates largely in the gray market, allowing direct consumer access to injectable stacks.

Users order customized combinations, known as stacks, from compounding pharmacies or online vendors. Business in this sector is expanding rapidly. Dhruv Khullar, a physician and New Yorker contributing writer, examined the industry by interviewing doctors and users, and tested a purchased stack in a lab.

Peptides were traditionally viewed as fragments of larger proteins, but recent research shows genes code for many small peptides directly.

These may serve as targets for new drugs. One doctor identified promising peptides and founded a company to advance one into clinical trials. The doctor emphasized the need for full testing before use.

Historical attempts to shortcut testing have led to adverse outcomes. Animal studies suggest potential benefits, but human data remains limited.

“People should not be taking them until they’re fully tested. The history of shortcuts is not a happy one.”

Many peptides sold lack human clinical evidence, relying on theoretical or preclinical work. Approximately 90 percent of drugs fail in clinical trials, highlighting the uncertainty. Random self-administration does not generate reliable data for informed decisions.